References

[1] Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med . 2006;166(9):955-964. doi:10.1001/archinte.166.9.955
[2] Barnett NL. Opportunities for collaboration between pharmacists and clinical pharmacologists to support medicines optimisation in the UK. Br J Clin Pharmacol . April 2019:bcp.13966. doi:10.1111/bcp.13966
[3] American College of Clinical Pharmacy. The Definition of Clinical Pharmacy. Pharmacotherapy . 2008;28(6):816-817. doi:10.1592/phco.28.6.816
[4] Treu CN, Llamzon JL, Acquisto NM, Lazar JD. The impact of an emergency medicine clinical pharmacist on nursing satisfaction.Int J Clin Pharm . 2019;41(6):1618-1624. doi:10.1007/s11096-019-00927-y
[5] Hampson N, Ruane S. The value of pharmacists in general practice: perspectives of general practitioners—an exploratory interview study. Int J Clin Pharm . 2019. doi:10.1007/s11096-019-00795-6
[6] Bedouch P, Charpiat B, Conort O, et al. Assessment of clinical pharmacists’ interventions in French Hospitals: Results of a multicenter study. Ann Pharmacother . 2008;42(7-8):1095-1103. doi:10.1345/aph.1L045
[7] Naseralallah LM, Hussain TA, Jaam M, Pawluk SA. Impact of pharmacist interventions on medication errors in hospitalized pediatric patients: a systematic review and meta-analysis. Int J Clin Pharm . April 2020:1-16. doi:10.1007/s11096-020-01034-z
[8] Sloeserwij VM, Hazen ACM, Zwart DLM, et al. Effects of non‐dispensing pharmacists integrated in general practice on medication‐related hospitalisations. Br J Clin Pharmacol . 2019;85(10):2321-2331. doi:10.1111/bcp.14041
[9] Renaudin P, Coste A, Audurier Y, et al. Clinical, Economic, and Organizational Impact of the Clinical Pharmacist in an Orthopedic and Trauma Surgery Department. J Patient Saf . October 2018:1. doi:10.1097/pts.0000000000000539
[10] Jourdan JP, Muzard A, Goyer I, et al. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital. Int J Clin Pharm . 2018;40(6):1474-1481. doi:10.1007/s11096-018-0733-6
[11] Zhai XB, Gu ZC, Liu XY. Clinical pharmacist intervention reduces mortality in patients with acute myocardial infarction: A propensity score matched analysis. Eur J Hosp Pharm . 2019;26(5):248-252. doi:10.1136/ejhpharm-2017-001344
[12] Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA . 2006;296(21):2563-2571. doi:10.1001/jama.296.21.joc60162
[13] Nazar H, Nazar Z, Portlock J, Todd A, Slight SP. A systematic review of the role of community pharmacies in improving the transition from secondary to primary care. Br J Clin Pharmacol . 2015;80(5):936-948. doi:10.1111/bcp.12718
[14] Abughosh SM, Wang X, Serna O, et al. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. J Manag care Spec Pharm . 2016;22(1):63-73. doi:10.18553/jmcp.2016.22.1.63
[15] Withidpanyawong U, Lerkiatbundit S, Saengcharoen W. Family-based intervention by pharmacists for type 2 diabetes: A randomised controlled trial. Patient Educ Couns . 2019;102(1):85-92. doi:10.1016/j.pec.2018.08.015
[16] Wilhelmsen NC, Eriksson T. Medication adherence interventions and outcomes: An overview of systematic reviews. Eur J Hosp Pharm. 2019;26(4):187-192. doi:10.1136/ejhpharm-2018-001725
[17] Adherence to Long-Term Therapies - Evidence for Action . World Health Organization; 2003. https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1.
[18] Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA . 1993;269(21):2779-2781.
[19] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med . 2005;353(5):487-497. doi:10.1056/NEJMra050100
[20] Ofori-Asenso R, Ilomäki J, Tacey M, et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol . 2019;85(1):227-235. doi:10.1111/bcp.13797
[21] Rasmussen JN, Chong A, Alter DA. Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction. JAMA . 2007;297(2):177. doi:10.1001/jama.297.2.177
[22] Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J . 2008;155(4):772-779. doi:10.1016/j.ahj.2007.12.011
[23] Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain . 2005;128(5):1016-1025. doi:10.1093/brain/awh467
[24] Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non‐adherence and adverse health outcomes in ageing populations: A systematic review and meta‐analysis. Br J Clin Pharmacol . 2019;85(11):2464-2478. doi:10.1111/bcp.14075
[25] Cutler DM, Everett W. Thinking Outside the Pillbox — Medication Adherence as a Priority for Health Care Reform. N Engl J Med . 2010;362(17):1553-1555. doi:10.1056/NEJMp1002305
[26] Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open . 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982
[27] Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: Options to consider. Int J Clin Pharm . 2014;36(1):55-69. doi:10.1007/s11096-013-9865-x
[28] Avataneo V, De Nicolò A, Rabbia F, et al. Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.Br J Clin Pharmacol . 2018;84(11):2535-2543. doi:10.1111/bcp.13706
[29] Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: A systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol . 2020;86(1):29-38. doi:10.1111/bcp.14164
[30] Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial.Int J Clin Pharm . 2011;33(1):132-140. doi:10.1007/s11096-010-9474-x
[31] Cheema E, Sutcliffe P, Singer DRJ. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials.Br J Clin Pharmacol . 2014;78(6):1238-1247. doi:10.1111/bcp.12452
[32] Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA . 2008;299(24):2857-2867. doi:10.1001/jama.299.24.2857
[33] Chabot I, Moisan J, Grégoire J-P, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother . 2003;37(9):1186-1193. doi:10.1345/aph.1C267
[34] Wallgren S, Berry-Cabán CS, Bowers L. Impact of clinical pharmacist intervention on diabetes-related outcomes in a military treatment facility. Ann Pharmacother . 2012;46(3):353-357. doi:10.1345/aph.1Q564
[35] Castejón AM, Calderón JL, Perez A, et al. A community-based pilot study of a diabetes pharmacist intervention in Latinos: impact on weight and hemoglobin A1c. J Health Care Poor Underserved . 2013;24(4 Suppl):48-60. doi:10.1353/hpu.2014.0003
[36] Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc . 2016;24(1):40-48. doi:10.1016/j.jsps.2015.02.023
[37] Cripps RJ, Gourley ES, Johnson W, et al. An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention. J Pharm Pract . 2011;24(3):332-338. doi:10.1177/0897190010392235
[38] Ali F, Laurin M-Y, Larivière C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels.Can J Clin Pharmacol . 2003;10(3):101-106.
[39] Tsuyuki RT, Olson KL, Dubyk AM, Schindel TJ, Johnson JA. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med . 2004;116(2):130-133. doi:10.1016/j.amjmed.2003.09.024.
[40] Cazarim M de S, de Freitas O, Penaforte TR, Achcar A, Pereira LRL. Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge. Fuchs FD, ed.PLoS One . 2016;11(6):e0155204. doi:10.1371/journal.pone.0155204
[41] Houle SKD, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Pharmacotherapy . 2012;32(6):527-537. doi:10.1002/j.1875-9114.2012.01097.x
[42] Hilleman DE, Faulkner MA, Monaghan MS. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy . 2004;24(8):1077-1083. doi:10.1592/phco.24.11.1077.36145
[43] Vegter S, Oosterhof P, van Boven JFM, Stuurman-Bieze AGG, Hiddink EG, Postma MJ. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag care Spec Pharm . 2014;20(7):722-732. doi:10.18553/jmcp.2014.20.7.722
[44] Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. J Hypertens . 2017;35(1):178-187. doi:10.1097/HJH.0000000000001126
[45] Wu W-C, Taveira TH, Jeffery S, et al. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. van Wouwe JP, ed. PLoS One . 2018;13(4):e0195898. doi:10.1371/journal.pone.0195898
[46] Gomes MS, Amorim WW, Morais RS, et al. Polypharmacy in older patients at primary care units in Brazil. Int J Clin Pharm . 2019;41(2):516-524. doi:10.1007/s11096-018-00780-5
[47] Chiapella LC, Montemarani Menna J, Mamprin ME. Assessment of polypharmacy in elderly patients by using data from dispensed medications in community pharmacies: analysis of results by using different methods of estimation. Int J Clin Pharm . 2018;40(5):987-990. doi:10.1007/s11096-018-0663-3
[48] Laven A, Arnet I. How pharmacists can encourage patient adherence to medicines. Pharm J . 2018;301(7916). doi:10.1211/PJ.2018.20205153
[49] Blacher J, Halimi J-M, Hanon O, et al. Prise en charge de l’hypertension artérielle de l’adulte. Recommandations 2013 de la Société française d’hypertension artérielle. Presse Med . 2013;42(5):819-825. doi:10.1016/j.lpm.2013.01.022
[50] Lupau D, Brion F, Halimi J-M, et al. Les entretiens pharmaceutiques dans l’hypertension artérielle à l’officine. Ann Cardiol Angeiol (Paris) . 2017;66(3):119-122. doi:10.1016/j.ancard.2017.05.001
[51] French High Health Authority (HAS) and French Medicine Agency (ANSM). Therapeutic Strategy for Glycemic Control of Type 2 Diabetes .; 2013. https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf. Accessed June 23, 2020.
[52] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol . 2014;63(25):2889-2934. doi:10.1016/j.jacc.2013.11.002
[53] Sackett D. Decide how to handle missing data in the analysis. In: Haynes R, Sackett D, Guyatt G, Tugwell P, eds. Clinical Epidemiology: How to Do Clinical Practice Research . ; 2012:128-129.
[54] Odeh M, Scullin C, Fleming G, Scott MG, Horne R, McElnay JC. Ensuring continuity of patient care across the healthcare interface: Telephone follow‐up post‐hospitalization. Br J Clin Pharmacol . 2019;85(3):616-625. doi:10.1111/bcp.13839
[55] Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther . 2001;23(8):1296-1310. http://www.ncbi.nlm.nih.gov/pubmed/11558866. Accessed May 3, 2019.
[56] Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care . 2009;15(6):e22-33. http://www.ncbi.nlm.nih.gov/pubmed/19514806. Accessed May 3, 2019.
[57] Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med . 2001;38(6):666-671. doi:10.1067/mem.2001.119456
[58] Huon J-F, Lenain E, LeGuen J, Chatellier G, Sabatier B, Saint-Jean O. How Drug Use by French Elderly Patients Has Changed During the Last Decade. Drugs - real world outcomes . 2015;2(4):327-333. doi:10.1007/s40801-015-0041-6
[59] Herr M, Robine J-M, Pinot J, Arvieu J-J, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf . 2015;24(6):637-646. doi:10.1002/pds.3772
[60] Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation . 1993;88(4 Pt 1):1973-1998. doi:10.1161/01.cir.88.4.1973
[61] Mayer O, Simon J, Heidrich J, Cokkinos D V, De Bacquer D, EUROASPIRE II Study Group. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health . 2004;58(1):47-52. doi:10.1136/jech.58.1.47
[62] Scholze J, Weinstock A, Kirchner F, Limberg R, Kreutz R. Impact of socio-economic factors on the long-term effectiveness of antihypertensive treatment with an angiotensin II receptor blocker: an observational study. Curr Med Res Opin . 2014;30(10):1947-1955. doi:10.1185/03007995.2014.929096
[63] Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther . 2011;36(5):602-613. doi:10.1111/j.1365-2710.2010.01218.x
[64] Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med . 2015;32(6):725-737. doi:10.1111/dme.12651
[65] Kandel O, Ripault A, Jourdain M, Bouche G. [Does the duration of medical consultations have an impact on the prescription of psychotropic drugs? Cross-sectional study carried out in general practice on 2,896 procedures]. Rev Prat . 2008;58(12 Suppl):19-24.
[66] Renaudin P, Boyer L, Esteve M-A, Bertault-Peres P, Auquier P, Honore S. Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis. Br J Clin Pharmacol . 2016;82(6):1660-1673. doi:10.1111/bcp.13085